Sacral neuromodulation device empowers patients with greater UUI control

In a recent interview, Andrea Pezzella, MD, URPS, FACOG, of Southern Urogynecology Wellness & Aesthetics in West Columbia, South Carolina, shared insights on Neuspera’s innovative integrated sacral neuromodulation (iSNM) system and its potential impact on managing urinary urgency incontinence (UUI). Unlike traditional neuromodulation therapies, the Neuspera iSNM device is minimally invasive and designed for greater patient autonomy, requiring only 2 hours of daily external disc wear. Pezzella emphasized that this limited daily commitment may actually enhance patient engagement and adherence. She said she believes that when patients take an active role in their therapy, they are more likely to remain consistent, particularly when they recognize how adherence directly influences their symptom control and quality of life.

Highlighting the device’s effectiveness, Pezzella noted that 42% of responders experienced complete resolution of UUI symptoms, along with significant improvements in quality of life. She envisions the Neuspera iSNM system as a valuable third-line treatment option, especially for patients who have not benefited from conservative therapies. In her practice, she incorporates the device into treatment discussions alongside other neuromodulation therapies and onabotulinumtoxinA, emphasizing the importance of shared decision-making.

Pezzella also stressed the need for offering patients comprehensive information on all available therapies. By doing so, physicians can build trust and confidence, ensuring patients feel empowered in their treatment journey. She views Neuspera’s technology as a meaningful advancement that addresses unmet needs in the current UUI treatment landscape—particularly for women—and enables providers to tailor therapy more precisely.

Overall, Pezzella positions the Neuspera iSNM device as a promising and patient-centered solution, combining efficacy, flexibility, and control to improve UUI management outcomes.